{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:11:52Z","timestamp":1777594312694,"version":"3.51.4"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Research and Development Program of China"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01755-w","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T11:23:25Z","timestamp":1771413805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pleural Mesothelioma: Current Therapeutic Strategies and Future Directions"],"prefix":"10.1007","volume":"28","author":[{"given":"Haoxuan","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingchen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Liang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyuan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming Q.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianyi","family":"Sha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"issue":"2","key":"1755_CR1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.6004\/jnccn.2024.0014","volume":"22","author":"J Stevenson","year":"2024","unstructured":"Stevenson J, Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, et al. NCCN guidelines\u00ae insights: mesothelioma: pleural, version 1.2024. J Natl Compr Canc Netw. 2024;22(2):72\u201381. https:\/\/doi.org\/10.6004\/jnccn.2024.0014.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"1755_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/ncponc0839","volume":"4","author":"A Tsiouris","year":"2007","unstructured":"Tsiouris A, Walesby RK. Malignant pleural mesothelioma: current concepts in treatment. Nat Clin Pract Oncol. 2007;4(6):344\u201352. https:\/\/doi.org\/10.1038\/ncponc0839.","journal-title":"Nat Clin Pract Oncol"},{"issue":"1","key":"1755_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/CCO.0000000000000697","volume":"33","author":"K Sinn","year":"2021","unstructured":"Sinn K, Mosleh B, Hoda MA. Malignant pleural mesothelioma: recent developments. Curr Opin Oncol. 2021;33(1):80\u20136. https:\/\/doi.org\/10.1097\/CCO.0000000000000697.","journal-title":"Curr Opin Oncol"},{"issue":"13","key":"1755_CR4","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMra1912719","volume":"385","author":"SM Janes","year":"2021","unstructured":"Janes SM, Alrifai D, Fennell DA. Perspectives on the treatment of malignant pleural mesothelioma. N Engl J Med. 2021;385(13):1207\u201318. https:\/\/doi.org\/10.1056\/NEJMra1912719.","journal-title":"N Engl J Med"},{"issue":"1","key":"1755_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-84108-6","volume":"15","author":"H Wang","year":"2025","unstructured":"Wang H, Yang R, Liu D, Li W. The presence of pleural effusion is an independent prognostic factor in patients with malignant pleural mesothelioma. Sci Rep. 2025;15(1):392. https:\/\/doi.org\/10.1038\/s41598-024-84108-6.","journal-title":"Sci Rep"},{"issue":"11","key":"1755_CR6","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s11912-022-01302-3","volume":"24","author":"ND Perera","year":"2022","unstructured":"Perera ND, Mansfield AS. The evolving therapeutic landscape for malignant pleural mesothelioma. Curr Oncol Rep. 2022;24(11):1413\u201323. https:\/\/doi.org\/10.1007\/s11912-022-01302-3.","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"1755_CR7","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s12094-020-02532-2","volume":"23","author":"E Nadal","year":"2021","unstructured":"Nadal E, Bosch-Barrera J, Cedr\u00e9s S, Coves J, Garc\u00eda-Campelo R, Guirado M, et al. SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020). Clin Transl Oncol. 2021;23(5):980\u20137. https:\/\/doi.org\/10.1007\/s12094-020-02532-2.","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"1755_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","volume":"33","author":"S Popat","year":"2022","unstructured":"Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up(\u2606). Ann Oncol. 2022;33(2):129\u201342. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.005.","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"1755_CR9","doi-asserted-by":"publisher","first-page":"S253","DOI":"10.21037\/jtd.2017.10.09","volume":"10","author":"A Bianco","year":"2018","unstructured":"Bianco A, Valente T, De Rimini ML, Sica G, Fiorelli A. Clinical diagnosis of malignant pleural mesothelioma. J Thorac Dis. 2018;10(Suppl 2):S253-s261. https:\/\/doi.org\/10.21037\/jtd.2017.10.09.","journal-title":"J Thorac Dis"},{"issue":"9","key":"1755_CR10","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.3390\/curroncol31090368","volume":"31","author":"E Roca","year":"2024","unstructured":"Roca E, Aujayeb A, Astoul P. Diagnosis of pleural mesothelioma: is everything solved at the present time? Curr Oncol. 2024;31(9):4968\u201383. https:\/\/doi.org\/10.3390\/curroncol31090368.","journal-title":"Curr Oncol"},{"issue":"26","key":"1755_CR11","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1111\/1759-7714.15022","volume":"14","author":"Q Wang","year":"2023","unstructured":"Wang Q, Xu C, Wang W, Zhang Y, Li Z, Song Z, et al. Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma. Thorac Cancer. 2023;14(26):2715\u201331. https:\/\/doi.org\/10.1111\/1759-7714.15022.","journal-title":"Thorac Cancer"},{"issue":"1","key":"1755_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09307-6","volume":"10","author":"Y Blum","year":"2019","unstructured":"Blum Y, Meiller C, Quetel L, Elarouci N, Ayadi M, Tashtanbaeva D, et al. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat Commun. 2019;10(1):1333. https:\/\/doi.org\/10.1038\/s41467-019-09307-6.","journal-title":"Nat Commun"},{"issue":"6","key":"1755_CR13","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1200\/jco.21.01567","volume":"40","author":"AS Tsao","year":"2022","unstructured":"Tsao AS, Pass HI, Rimner A, Mansfield AS. New era for malignant pleural mesothelioma: updates on therapeutic options. J Clin Oncol. 2022;40(6):681\u201392. https:\/\/doi.org\/10.1200\/jco.21.01567.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1755_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407\u201316. https:\/\/doi.org\/10.1038\/ng.3520.","journal-title":"Nat Genet"},{"issue":"11","key":"1755_CR15","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","volume":"127","author":"S Hiltbrunner","year":"2022","unstructured":"Hiltbrunner S, Fleischmann Z, Sokol ES, Zoche M, Felley-Bosco E, Curioni-Fontecedro A. Genomic landscape of pleural and peritoneal mesothelioma tumours. Br J Cancer. 2022;127(11):1997\u20132005. https:\/\/doi.org\/10.1038\/s41416-022-01979-0.","journal-title":"Br J Cancer"},{"issue":"8","key":"1755_CR16","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/s41416-021-01462-2","volume":"125","author":"J Obacz","year":"2021","unstructured":"Obacz J, Yung H, Shamseddin M, Linnane E, Liu X, Azad AA, et al. Biological basis for novel mesothelioma therapies. Br J Cancer. 2021;125(8):1039\u201355. https:\/\/doi.org\/10.1038\/s41416-021-01462-2.","journal-title":"Br J Cancer"},{"issue":"8","key":"1755_CR17","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00595-015-1275-3","volume":"46","author":"T Takuwa","year":"2016","unstructured":"Takuwa T, Hasegawa S. Current surgical strategies for malignant pleural mesothelioma. Surg Today. 2016;46(8):887\u201394. https:\/\/doi.org\/10.1007\/s00595-015-1275-3.","journal-title":"Surg Today"},{"issue":"Suppl 2","key":"1755_CR18","doi-asserted-by":"publisher","first-page":"S298","DOI":"10.21037\/jtd.2018.01.44","volume":"10","author":"P Solli","year":"2018","unstructured":"Solli P, Brandolini J, Pardolesi A, Nardini M, Lacava N, Parri SF, et al. Diaphragmatic and pericardial reconstruction after surgery for malignant pleural mesothelioma. J Thorac Dis. 2018;10(Suppl 2):S298-s303. https:\/\/doi.org\/10.21037\/jtd.2018.01.44.","journal-title":"J Thorac Dis"},{"issue":"Suppl 1","key":"1755_CR19","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.21037\/tlcr.2020.01.08","volume":"9","author":"GA Woodard","year":"2020","unstructured":"Woodard GA, Jablons DM. Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma. Transl Lung Cancer Res. 2020;9(Suppl 1):S86-s91. https:\/\/doi.org\/10.21037\/tlcr.2020.01.08.","journal-title":"Transl Lung Cancer Res"},{"issue":"11","key":"1755_CR20","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2017.04.05","volume":"5","author":"DA Waller","year":"2017","unstructured":"Waller DA, Dawson AG. Randomized controlled trials in malignant pleural mesothelioma surgery-mistakes made and lessons learned. Ann Transl Med. 2017;5(11):240. https:\/\/doi.org\/10.21037\/atm.2017.04.05.","journal-title":"Ann Transl Med"},{"issue":"11","key":"1755_CR21","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.jtho.2018.08.001","volume":"13","author":"R Bueno","year":"2018","unstructured":"Bueno R, Opitz I. Surgery in malignant pleural mesothelioma. J Thorac Oncol. 2018;13(11):1638\u201354. https:\/\/doi.org\/10.1016\/j.jtho.2018.08.001.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"1755_CR22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.thorsurg.2020.08.006","volume":"30","author":"KE Rosenzweig","year":"2020","unstructured":"Rosenzweig KE. Radiation therapy for malignant pleural mesothelioma. Thorac Surg Clin. 2020;30(4):473\u201380. https:\/\/doi.org\/10.1016\/j.thorsurg.2020.08.006.","journal-title":"Thorac Surg Clin"},{"issue":"9","key":"1755_CR23","doi-asserted-by":"publisher","first-page":"e532","DOI":"10.1016\/s1470-2045(17)30459-x","volume":"18","author":"M de Perrot","year":"2017","unstructured":"de Perrot M, Wu L, Wu M, Cho BCJ. Radiotherapy for the treatment of malignant pleural mesothelioma. Lancet Oncol. 2017;18(9):e532\u201342. https:\/\/doi.org\/10.1016\/s1470-2045(17)30459-x.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1755_CR24","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/1754-9485.12636","volume":"61","author":"F Foroudi","year":"2017","unstructured":"Foroudi F, Smith JG, Putt F, Wada M. High-dose palliative radiotherapy for malignant pleural mesothelioma. J Med Imaging Radiat Oncol. 2017;61(6):797\u2013803. https:\/\/doi.org\/10.1111\/1754-9485.12636.","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"14","key":"1755_CR25","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/jco.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344. https:\/\/doi.org\/10.1200\/jco.2003.11.136.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1755_CR26","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/s2213-2600(20)30362-3","volume":"9","author":"CJ de Gooijer","year":"2021","unstructured":"de Gooijer CJ, van der Noort V, Stigt JA, Baas P, Biesma B, Cornelissen R, et al. Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial. Lancet Respir Med. 2021;9(6):585\u201392. https:\/\/doi.org\/10.1016\/s2213-2600(20)30362-3.","journal-title":"Lancet Respir Med"},{"issue":"8","key":"1755_CR27","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.jtho.2024.01.018","volume":"19","author":"AS Wolf","year":"2024","unstructured":"Wolf AS, Eisele M, Giroux DJ, Gill R, Nowak AK, Bille A, et al. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: expanded database to inform revisions in the ninth edition of the TNM Classification of Pleural Mesothelioma. J Thorac Oncol. 2024;19(8):1242\u201352. https:\/\/doi.org\/10.1016\/j.jtho.2024.01.018.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"1755_CR28","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.jtho.2024.03.007","volume":"19","author":"RR Gill","year":"2024","unstructured":"Gill RR, Nowak AK, Giroux DJ, Eisele M, Rosenthal A, Kindler H, et al. The International Association for the Study of Lung Cancer Mesothelioma Staging Project: proposals for revisions of the \u201cT\u201d descriptors in the forthcoming ninth edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2024;19(9):1310\u201325. https:\/\/doi.org\/10.1016\/j.jtho.2024.03.007.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"1755_CR29","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.jtho.2024.05.003","volume":"19","author":"A Bille","year":"2024","unstructured":"Bille A, Ripley RT, Giroux DJ, Gill RR, Kindler HL, Nowak AK, et al. The international association for the study of lung cancer mesothelioma staging project: proposals for the N descriptors in the forthcoming ninth edition of the TNM classification for pleural mesothelioma. J Thorac Oncol. 2024;19(9):1326\u201338. https:\/\/doi.org\/10.1016\/j.jtho.2024.05.003.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"1755_CR30","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jtho.2024.08.022","volume":"19","author":"HL Kindler","year":"2024","unstructured":"Kindler HL, Rosenthal A, Giroux DJ, Nowak AK, Bill\u00e8 A, Gill RR, et al. The International Association for the Study of Lung Cancer Mesothelioma Staging Project: proposals for the M descriptors in the forthcoming ninth edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2024;19(11):1564\u201377. https:\/\/doi.org\/10.1016\/j.jtho.2024.08.022.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"1755_CR31","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","volume":"17","author":"JL Sauter","year":"2022","unstructured":"Sauter JL, Dacic S, Galateau-Salle F, Attanoos RL, Butnor KJ, Churg A, et al. The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification. J Thorac Oncol. 2022;17(5):608\u201322. https:\/\/doi.org\/10.1016\/j.jtho.2021.12.014.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"1755_CR32","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):1022\u20135. https:\/\/doi.org\/10.1038\/ng.912.","journal-title":"Nat Genet"},{"issue":"1","key":"1755_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00640-3","volume":"11","author":"DA Fennell","year":"2025","unstructured":"Fennell DA, Sekido Y, Baas P, Husain AN, Curioni-Fontecedro A, Lim E, et al. Pleural mesothelioma. Nat Rev Dis Primers. 2025;11(1):56. https:\/\/doi.org\/10.1038\/s41572-025-00640-3.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"1755_CR34","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/s0022-5223(98)70274-0","volume":"115","author":"HI Pass","year":"1998","unstructured":"Pass HI, Temeck BK, Kranda K, Steinberg SM, Feuerstein IR. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1998;115(2):310\u20137. https:\/\/doi.org\/10.1016\/s0022-5223(98)70274-0.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"1755_CR35","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1067\/mtc.2001.116560","volume":"122","author":"VW Rusch","year":"2001","unstructured":"Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122(4):788\u201395. https:\/\/doi.org\/10.1067\/mtc.2001.116560.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"8","key":"1755_CR36","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1158\/1078-0432.Ccr-20-4037","volume":"27","author":"K Oehl","year":"2021","unstructured":"Oehl K, Vrugt B, Wagner U, Kirschner MB, Meerang M, Weder W, et al. Alterations in BAP1 are associated with cisplatin resistance through inhibition of apoptosis in malignant pleural mesothelioma. Clin Cancer Res. 2021;27(8):2277\u201391. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-4037.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1755_CR37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/s2213-2600(24)00119-x","volume":"12","author":"E Lim","year":"2024","unstructured":"Lim E, Waller D, Lau K, Steele J, Pope A, Ali C, et al. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. Lancet Respir Med. 2024;12(6):457\u201366. https:\/\/doi.org\/10.1016\/s2213-2600(24)00119-x.","journal-title":"Lancet Respir Med"},{"key":"1755_CR38","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02114-2023","author":"J Raskin","year":"2024","unstructured":"Raskin J, Surmont V, Maat A, Yahia M, Burgers SA, Pretzenbacher Y, et al. A randomised phase II study of extended pleurectomy\/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma: EORTC 1205. Eur Respir J. 2024. https:\/\/doi.org\/10.1183\/13993003.02114-2023.","journal-title":"Eur Respir J"},{"issue":"2","key":"1755_CR39","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/s1470-2045(20)30606-9","volume":"22","author":"BCJ Cho","year":"2021","unstructured":"Cho BCJ, Donahoe L, Bradbury PA, Leighl N, Keshavjee S, Hope A, et al. Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. Lancet Oncol. 2021;22(2):190\u20137. https:\/\/doi.org\/10.1016\/s1470-2045(20)30606-9.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1755_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-025-03748-8","volume":"23","author":"HH Elsayed","year":"2025","unstructured":"Elsayed HH, Elanany MEE, ElSayegh MT, Hassaballa AS, Abdel-Gayed M. Hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma after cytoreductive surgical procedures: a systematic review. World J Surg Oncol. 2025;23(1):132. https:\/\/doi.org\/10.1186\/s12957-025-03748-8.","journal-title":"World J Surg Oncol"},{"issue":"2","key":"1755_CR41","doi-asserted-by":"publisher","first-page":"187","DOI":"10.21037\/tlcr-23-46","volume":"12","author":"K Branch","year":"2023","unstructured":"Branch K, Adusumilli PS, Zauderer MG. Some like it hot: the potential role of hyperthermic intrathoracic chemotherapy in the multimodality treatment of pleural mesothelioma. Transl Lung Cancer Res. 2023;12(2):187\u20139. https:\/\/doi.org\/10.21037\/tlcr-23-46.","journal-title":"Transl Lung Cancer Res"},{"issue":"11","key":"1755_CR42","doi-asserted-by":"publisher","first-page":"960","DOI":"10.21037\/atm-20-7247","volume":"9","author":"M Migliore","year":"2021","unstructured":"Migliore M, Ried M, Molins L, Lucchi M, Ambrogi M, Molnar TF, et al. Hyperthermic intrathoracic chemotherapy (HITHOC) should be included in the guidelines for malignant pleural mesothelioma. Ann Transl Med. 2021;9(11):960. https:\/\/doi.org\/10.21037\/atm-20-7247.","journal-title":"Ann Transl Med"},{"issue":"10","key":"1755_CR43","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1200\/op-25-00035","volume":"21","author":"HL Kindler","year":"2025","unstructured":"Kindler HL, Dagogo-Jack I, de Perrot M, Drazer MW, Ismaila N, Hassan R. Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights. JCO Oncol Pract. 2025;21(10):1413\u20136. https:\/\/doi.org\/10.1200\/op-25-00035.","journal-title":"JCO Oncol Pract"},{"issue":"9","key":"1755_CR44","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.jtho.2018.04.032","volume":"13","author":"BM Burt","year":"2018","unstructured":"Burt BM, Richards WG, Lee HS, Bartel S, Dasilva MC, Gill RR, et al. A phase i trial of surgical resection and intraoperative hyperthermic cisplatin and gemcitabine for pleural mesothelioma. J Thorac Oncol. 2018;13(9):1400\u20139. https:\/\/doi.org\/10.1016\/j.jtho.2018.04.032.","journal-title":"J Thorac Oncol"},{"key":"1755_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.886430","volume":"12","author":"AY Choi","year":"2022","unstructured":"Choi AY, Singh A, Wang D, Pittala K, Hoang CD. Current state of pleural-directed adjuncts against malignant pleural mesothelioma. Front Oncol. 2022;12:886430. https:\/\/doi.org\/10.3389\/fonc.2022.886430.","journal-title":"Front Oncol"},{"issue":"12","key":"1755_CR46","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1007\/s11095-024-03794-z","volume":"41","author":"NS Kulkarni","year":"2024","unstructured":"Kulkarni NS, Chauhan G, Quadros M, Gadhave DG, Gupta V. Development and in-vitro evaluation of doxorubicin-loaded methacrylate gelatin (GelMa)-acrylamide hydrogels for the treatment of malignant pleural mesothelioma. Pharm Res. 2024;41(12):2331\u201345. https:\/\/doi.org\/10.1007\/s11095-024-03794-z.","journal-title":"Pharm Res"},{"key":"1755_CR47","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ejmech.2017.07.063","volume":"142","author":"G Facchetti","year":"2017","unstructured":"Facchetti G, Petrella F, Spaggiari L, Rimoldi I. Malignant pleural mesothelioma: state of the art and advanced cell therapy. Eur J Med Chem. 2017;142:266\u201370. https:\/\/doi.org\/10.1016\/j.ejmech.2017.07.063.","journal-title":"Eur J Med Chem"},{"key":"1755_CR48","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2147\/ijn.S186344","volume":"14","author":"E Cova","year":"2019","unstructured":"Cova E, Pandolfi L, Colombo M, Frangipane V, Inghilleri S, Morosini M, et al. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study. Int J Nanomedicine. 2019;14:773\u201385. https:\/\/doi.org\/10.2147\/ijn.S186344.","journal-title":"Int J Nanomedicine"},{"issue":"Suppl 2","key":"1755_CR49","doi-asserted-by":"publisher","first-page":"S194","DOI":"10.21037\/jtd.2017.10.12","volume":"10","author":"F Sonvico","year":"2018","unstructured":"Sonvico F, Barbieri S, Colombo P, Mucchino C, Barocelli E, Cantoni AM, et al. Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma. J Thorac Dis. 2018;10(Suppl 2):S194-s206. https:\/\/doi.org\/10.21037\/jtd.2017.10.12.","journal-title":"J Thorac Dis"},{"issue":"Suppl 2","key":"1755_CR50","doi-asserted-by":"publisher","first-page":"S311","DOI":"10.21037\/jtd.2017.10.131","volume":"10","author":"PA Zucali","year":"2018","unstructured":"Zucali PA. Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma. J Thorac Dis. 2018;10(Suppl 2):S311-s321. https:\/\/doi.org\/10.21037\/jtd.2017.10.131.","journal-title":"J Thorac Dis"},{"issue":"10026","key":"1755_CR51","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/s0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405\u201314. https:\/\/doi.org\/10.1016\/s0140-6736(15)01238-6.","journal-title":"Lancet"},{"issue":"4","key":"1755_CR52","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2022.2522","volume":"16","author":"E Rijavec","year":"2022","unstructured":"Rijavec E, Biello F, Barletta G, Dellepiane C, Genova C. Novel approaches for the treatment of unresectable malignant pleural mesothelioma: a focus on immunotherapy and target therapy (Review). Mol Clin Oncol. 2022;16(4):89. https:\/\/doi.org\/10.3892\/mco.2022.2522.","journal-title":"Mol Clin Oncol"},{"key":"1755_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102520","volume":"61","author":"G Levallet","year":"2025","unstructured":"Levallet G, Creveuil C, L\u00e9ger-Vigot A, Brosseau S, Danel C, Scherpereel A, et al. MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial. Transl Oncol. 2025;61:102520. https:\/\/doi.org\/10.1016\/j.tranon.2025.102520.","journal-title":"Transl Oncol"},{"issue":"10","key":"1755_CR54","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-021-00883-8","volume":"22","author":"E Dudnik","year":"2021","unstructured":"Dudnik E, Reinhorn D, Holtzman L. Novel and promising systemic treatment approaches in mesothelioma. Curr Treat Options Oncol. 2021;22(10):89. https:\/\/doi.org\/10.1007\/s11864-021-00883-8.","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"1755_CR55","doi-asserted-by":"publisher","first-page":"295","DOI":"10.21037\/tlcr.2017.06.01","volume":"6","author":"MR Mancuso","year":"2017","unstructured":"Mancuso MR, Neal JW. Novel systemic therapy against malignant pleural mesothelioma. Transl Lung Cancer Res. 2017;6(3):295\u2013314. https:\/\/doi.org\/10.21037\/tlcr.2017.06.01.","journal-title":"Transl Lung Cancer Res"},{"issue":"31","key":"1755_CR56","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1200\/jco.2017.72.9012","volume":"35","author":"F Grosso","year":"2017","unstructured":"Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, et al. Nintedanib plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial. J Clin Oncol. 2017;35(31):3591\u2013600. https:\/\/doi.org\/10.1200\/jco.2017.72.9012.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1755_CR57","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/s2213-2600(19)30139-0","volume":"7","author":"GV Scagliotti","year":"2019","unstructured":"Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2019;7(7):569\u201380. https:\/\/doi.org\/10.1016\/s2213-2600(19)30139-0.","journal-title":"Lancet Respir Med"},{"issue":"8","key":"1755_CR58","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.jtho.2017.05.021","volume":"12","author":"AS Tsao","year":"2017","unstructured":"Tsao AS, Moon J, Wistuba II, Vogelzang NJ, Kalemkerian GP, Redman MW, et al. Phase I trial of cediranib in combination with cisplatin and pemetrexed in chemonaive patients with unresectable malignant pleural mesothelioma (SWOG S0905). J Thorac Oncol. 2017;12(8):1299\u2013308. https:\/\/doi.org\/10.1016\/j.jtho.2017.05.021.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"1755_CR59","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/s1470-2045(18)30193-1","volume":"19","author":"V Gregorc","year":"2018","unstructured":"Gregorc V, Gaafar RM, Favaretto A, Grossi F, Jassem J, Polychronis A, et al. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2018;19(6):799\u2013811. https:\/\/doi.org\/10.1016\/s1470-2045(18)30193-1.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1755_CR60","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/s1470-2045(21)00404-6","volume":"22","author":"C Pinto","year":"2021","unstructured":"Pinto C, Zucali PA, Pagano M, Grosso F, Pasello G, Garassino MC, et al. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021;22(10):1438\u201347. https:\/\/doi.org\/10.1016\/s1470-2045(21)00404-6.","journal-title":"Lancet Oncol"},{"key":"1755_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15245787","author":"S Cedres","year":"2023","unstructured":"Cedres S, Valdivia A, Iranzo P, Callejo A, Pardo N, Navarro A, et al. Current state-of-the-art therapy for malignant pleural mesothelioma and future options centered on immunotherapy. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15245787.","journal-title":"Cancers (Basel)"},{"issue":"28","key":"1755_CR62","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.2217\/fon-2017-0307","volume":"13","author":"S Brosseau","year":"2017","unstructured":"Brosseau S, Assoun S, Naltet C, Steinmetz C, Gounant V, Zalcman G. A review of bevacizumab in the treatment of malignant pleural mesothelioma. Future Oncol. 2017;13(28):2537\u201346. https:\/\/doi.org\/10.2217\/fon-2017-0307.","journal-title":"Future Oncol"},{"key":"1755_CR63","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bcp.2016.07.012","volume":"123","author":"MA Bonelli","year":"2017","unstructured":"Bonelli MA, Fumarola C, Monica SL, Alfieri R. New therapeutic strategies for malignant pleural mesothelioma. Biochem Pharmacol. 2017;123:8\u201318. https:\/\/doi.org\/10.1016\/j.bcp.2016.07.012.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"1755_CR64","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.lungcan.2012.07.005","volume":"78","author":"B Fischer","year":"2012","unstructured":"Fischer B, Frei C, Moura U, Stahel R, Felley-Bosco E. Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy. Lung Cancer. 2012;78(1):23\u20139. https:\/\/doi.org\/10.1016\/j.lungcan.2012.07.005.","journal-title":"Lung Cancer"},{"key":"1755_CR65","doi-asserted-by":"publisher","unstructured":"Pignochino Y, Dell\u2019Aglio C, Inghilleri S, Zorzetto M, Basiric\u00f2 M, Capozzi F, et al. The combination of Sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma. BMC Cancer. 2015;15:374. https:\/\/doi.org\/10.1186\/s12885-015-1363-1.","DOI":"10.1186\/s12885-015-1363-1."},{"key":"1755_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.102815","volume":"144","author":"M Cinausero","year":"2019","unstructured":"Cinausero M, Rihawi K, Cortiula F, Follador A, Fasola G, Ardizzoni A. Emerging therapies in malignant pleural mesothelioma. Crit Rev Oncol Hematol. 2019;144:102815. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.102815.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"1755_CR67","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","volume":"37","author":"DA Fennell","year":"2019","unstructured":"Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, et al. Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND\u2014a double-blind, randomized, phase II study. J Clin Oncol. 2019;37(10):790\u20138. https:\/\/doi.org\/10.1200\/JCO.2018.79.0543.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1755_CR68","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/cjp2.218","volume":"7","author":"H Ollila","year":"2021","unstructured":"Ollila H, Paajanen J, Wolff H, Ilonen I, Sutinen E, V\u00e4lim\u00e4ki K, et al. High tumor cell platelet-derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma. J Pathol Clin Res. 2021;7(5):482\u201394. https:\/\/doi.org\/10.1002\/cjp2.218.","journal-title":"J Pathol Clin Res"},{"issue":"3","key":"1755_CR69","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.cllc.2013.12.008","volume":"15","author":"AS Tsao","year":"2014","unstructured":"Tsao AS, Harun N, Lee JJ, Heymach J, Pisters K, Hong WK, et al. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. Clin Lung Cancer. 2014;15(3):197\u2013201. https:\/\/doi.org\/10.1016\/j.cllc.2013.12.008.","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"1755_CR70","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s10528-023-10426-5","volume":"62","author":"A Mejia-Garcia","year":"2024","unstructured":"Mejia-Garcia A, Bonilla DA, Ramirez CM, Escobar-D\u00edaz FA, Combita AL, Forero DA, et al. Genes and pathways involved in the progression of malignant pleural mesothelioma: a meta-analysis of genome-wide expression studies. Biochem Genet. 2024;62(1):352\u201370. https:\/\/doi.org\/10.1007\/s10528-023-10426-5.","journal-title":"Biochem Genet"},{"issue":"1","key":"1755_CR71","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1073\/pnas.1309085110","volume":"111","author":"H Yu","year":"2014","unstructured":"Yu H, Pak H, Hammond-Martel I, Ghram M, Rodrigue A, Daou S, et al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad Sci U S A. 2014;111(1):285\u201390. https:\/\/doi.org\/10.1073\/pnas.1309085110.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1755_CR72","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/s2213-2600(20)30390-8","volume":"9","author":"DA Fennell","year":"2021","unstructured":"Fennell DA, King A, Mohammed S, Branson A, Brookes C, Darlison L, et al. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. Lancet Respir Med. 2021;9(6):593\u2013600. https:\/\/doi.org\/10.1016\/s2213-2600(20)30390-8.","journal-title":"Lancet Respir Med"},{"issue":"12","key":"1755_CR73","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1007\/s11864-023-01148-2","volume":"24","author":"A John","year":"2023","unstructured":"John A, O\u2019Sullivan H, Popat S. Updates in management of malignant pleural mesothelioma. Curr Treat Options Oncol. 2023;24(12):1758\u201389. https:\/\/doi.org\/10.1007\/s11864-023-01148-2.","journal-title":"Curr Treat Options Oncol"},{"key":"1755_CR74","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.lungcan.2020.10.020","volume":"150","author":"K Marshall","year":"2020","unstructured":"Marshall K, Jackson S, Jones J, Holme J, Lyons J, Barrett E, et al. Homozygous deletion of CDKN2A in malignant mesothelioma: diagnostic utility, patient characteristics and survival in a UK mesothelioma centre. Lung Cancer. 2020;150:195\u2013200. https:\/\/doi.org\/10.1016\/j.lungcan.2020.10.020.","journal-title":"Lung Cancer"},{"issue":"3","key":"1755_CR75","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/s1470-2045(22)00062-6","volume":"23","author":"DA Fennell","year":"2022","unstructured":"Fennell DA, King A, Mohammed S, Greystoke A, Anthony S, Poile C, et al. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. Lancet Oncol. 2022;23(3):374\u201381. https:\/\/doi.org\/10.1016\/s1470-2045(22)00062-6.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1755_CR76","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1001\/jamaoncol.2023.6789","volume":"10","author":"PW Szlosarek","year":"2024","unstructured":"Szlosarek PW, Creelan BC, Sarkodie T, Nolan L, Taylor P, Olevsky O, et al. Pegargiminase plus first-line chemotherapy in patients with nonepithelioid pleural mesothelioma: the ATOMIC-Meso randomized clinical trial. JAMA Oncol. 2024;10(4):475\u201383. https:\/\/doi.org\/10.1001\/jamaoncol.2023.6789.","journal-title":"JAMA Oncol"},{"key":"1755_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00105","volume":"10","author":"G Reid","year":"2020","unstructured":"Reid G, Johnson TG, van Zandwijk N. Manipulating microRNAs for the treatment of malignant pleural mesothelioma: past, present and future. Front Oncol. 2020;10:105. https:\/\/doi.org\/10.3389\/fonc.2020.00105.","journal-title":"Front Oncol"},{"issue":"8","key":"1755_CR78","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2217\/epi-2016-0035","volume":"8","author":"G Reid","year":"2016","unstructured":"Reid G, Kao SC, Pavlakis N, Brahmbhatt H, MacDiarmid J, Clarke S, et al. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics. 2016;8(8):1079\u201385. https:\/\/doi.org\/10.2217\/epi-2016-0035.","journal-title":"Epigenomics"},{"issue":"5","key":"1755_CR79","first-page":"1118","volume":"6","author":"HY Lee","year":"2016","unstructured":"Lee HY, Mohammed KA, Nasreen N. Nanoparticle-based targeted gene therapy for lung cancer. Am J Cancer Res. 2016;6(5):1118\u201334.","journal-title":"Am J Cancer Res"},{"issue":"1\u20132","key":"1755_CR80","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ijpharm.2014.08.019","volume":"474","author":"MH Qu","year":"2014","unstructured":"Qu MH, Zeng RF, Fang S, Dai QS, Li HP, Long JT. Liposome-based co-delivery of SiRNA and docetaxel for the synergistic treatment of lung cancer. Int J Pharm. 2014;474(1\u20132):112\u201322. https:\/\/doi.org\/10.1016\/j.ijpharm.2014.08.019.","journal-title":"Int J Pharm"},{"issue":"1","key":"1755_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03283-0","volume":"44","author":"M Piccioni","year":"2025","unstructured":"Piccioni M, Di Meo F, Valentino A, Campani V, Arigoni M, Tanori M, et al. miRNA-503 inhibition exerts anticancer effects and reduces tumor growth in mesothelioma. J Exp Clin Cancer Res. 2025;44(1):65. https:\/\/doi.org\/10.1186\/s13046-025-03283-0.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1755_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-12624-4","volume":"12","author":"M Ichikawa","year":"2022","unstructured":"Ichikawa M, Muramatsu N, Matsunaga W, Ishikawa T, Okuda T, Okamoto H, et al. Effects of inhalable gene transfection as a novel gene therapy for non-small cell lung cancer and malignant pleural mesothelioma. Sci Rep. 2022;12(1):8634. https:\/\/doi.org\/10.1038\/s41598-022-12624-4.","journal-title":"Sci Rep"},{"issue":"15","key":"1755_CR83","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1158\/1078-0432.Ccr-15-2133","volume":"22","author":"DH Sterman","year":"2016","unstructured":"Sterman DH, Alley E, Stevenson JP, Friedberg J, Metzger S, Recio A, et al. Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFN\u03b1 combined with chemotherapy. Clin Cancer Res. 2016;22(15):3791\u2013800. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-2133.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1755_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101763","volume":"5","author":"R Zhu","year":"2024","unstructured":"Zhu R, Liu X, Zhang X, Zhong Z, Qi S, Jin R, et al. Gene therapy for diffuse pleural mesotheliomas in preclinical models by concurrent expression of NF2 and SuperHippo. Cell Rep Med. 2024;5(10):101763. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101763.","journal-title":"Cell Rep Med"},{"issue":"9","key":"1755_CR85","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41571-022-00649-7","volume":"19","author":"DA Fennell","year":"2022","unstructured":"Fennell DA, Dulloo S, Harber J. Immunotherapy approaches for malignant pleural mesothelioma. Nat Rev Clin Oncol. 2022;19(9):573\u201384. https:\/\/doi.org\/10.1038\/s41571-022-00649-7.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"1755_CR86","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.21037\/tlcr-20-673","volume":"10","author":"J Menis","year":"2021","unstructured":"Menis J, Pasello G, Remon J. Immunotherapy in malignant pleural mesothelioma: a review of literature data. Transl Lung Cancer Res. 2021;10(6):2988\u20133000. https:\/\/doi.org\/10.21037\/tlcr-20-673.","journal-title":"Transl Lung Cancer Res"},{"key":"1755_CR87","doi-asserted-by":"publisher","unstructured":"Nicolini F, Bocchini M, Bronte G, Delmonte A, Guidoboni M, Crin\u00f2 L, et al. Malignant pleural mesothelioma: state-of-the-art on current therapies and promises for the future. Front Oncol. 2019;9:1519. https:\/\/doi.org\/10.3389\/fonc.2019.01519.","DOI":"10.3389\/fonc.2019.01519."},{"issue":"9","key":"1755_CR88","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/s1470-2045(17)30446-1","volume":"18","author":"M Maio","year":"2017","unstructured":"Maio M, Scherpereel A, Calabr\u00f2 L, Aerts J, Perez SC, Bearz A, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18(9):1261\u201373. https:\/\/doi.org\/10.1016\/s1470-2045(17)30446-1.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1755_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.opresp.2024.100323","volume":"6","author":"R L\u00f3pez-Castro","year":"2024","unstructured":"L\u00f3pez-Castro R, Fuentes-Mart\u00edn \u00c1, Medina Del Valle A, Garc\u00eda Pe\u00f1a T, Soro Garc\u00eda J, L\u00f3pez Gonz\u00e1lez L, et al. Advances in immunotherapy for malignant pleural mesothelioma: from emerging strategies to translational insights. Open Respir Arch. 2024;6(3):100323. https:\/\/doi.org\/10.1016\/j.opresp.2024.100323.","journal-title":"Open Respir Arch"},{"issue":"36","key":"1755_CR90","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1200\/jco.2017.74.5471","volume":"35","author":"JS Frenel","year":"2017","unstructured":"Frenel JS, Le Tourneau C, O\u2019Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol. 2017;35(36):4035\u201341. https:\/\/doi.org\/10.1200\/jco.2017.74.5471.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1755_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100188","volume":"2","author":"RY Kim","year":"2021","unstructured":"Kim RY, Mitra N, Bagley SJ, Marmarelis ME, Haas AR, Rendle KA, et al. Immune checkpoint inhibitor uptake in real-world patients with malignant pleural mesothelioma. JTO Clin Res Rep. 2021;2(6):100188. https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100188.","journal-title":"JTO Clin Res Rep"},{"key":"1755_CR92","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.lungcan.2021.06.017","volume":"159","author":"RY Kim","year":"2021","unstructured":"Kim RY, Li Y, Marmarelis ME, Vachani A. Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma. Lung Cancer. 2021;159:107\u201310. https:\/\/doi.org\/10.1016\/j.lungcan.2021.06.017.","journal-title":"Lung Cancer"},{"issue":"5","key":"1755_CR93","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33(5):488\u201399. https:\/\/doi.org\/10.1016\/j.annonc.2022.01.074.","journal-title":"Ann Oncol"},{"issue":"1","key":"1755_CR94","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-04200-9","volume":"17","author":"T Yoshida","year":"2025","unstructured":"Yoshida T, Kuribayashi K. Immunotherapy for pleural mesothelioma: from innovation to the frontlines of core clinical questions. Discov Oncol. 2025;17(1):43. https:\/\/doi.org\/10.1007\/s12672-025-04200-9.","journal-title":"Discov Oncol"},{"issue":"10419","key":"1755_CR95","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/s0140-6736(23)01613-6","volume":"402","author":"Q Chu","year":"2023","unstructured":"Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023;402(10419):2295\u2013306. https:\/\/doi.org\/10.1016\/s0140-6736(23)01613-6.","journal-title":"Lancet"},{"issue":"12","key":"1755_CR96","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1038\/s41591-025-03958-3","volume":"31","author":"JE Reuss","year":"2025","unstructured":"Reuss JE, Lee PK, Mehran RJ, Hu C, Ke S, Jamali A, et al. Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses. Nat Med. 2025;31(12):4097\u2013108. https:\/\/doi.org\/10.1038\/s41591-025-03958-3.","journal-title":"Nat Med"},{"issue":"11","key":"1755_CR97","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","volume":"27","author":"PM Forde","year":"2021","unstructured":"Forde PM, Anagnostou V, Sun Z, Dahlberg SE, Kindler HL, Niknafs N, et al. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 2021;27(11):1910\u201320. https:\/\/doi.org\/10.1038\/s41591-021-01541-0.","journal-title":"Nat Med"},{"issue":"2","key":"1755_CR98","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41565-021-01032-w","volume":"17","author":"Y Liu","year":"2022","unstructured":"Liu Y, Wang L, Song Q, Ali M, Crowe WN, Kucera GL, et al. Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion. Nat Nanotechnol. 2022;17(2):206\u201316. https:\/\/doi.org\/10.1038\/s41565-021-01032-w.","journal-title":"Nat Nanotechnol"},{"issue":"23","key":"1755_CR99","doi-asserted-by":"publisher","first-page":"8284","DOI":"10.12998\/wjcc.v10.i23.8284","volume":"10","author":"TT Xuan","year":"2022","unstructured":"Xuan TT, Li GY, Meng SB, Wang ZM, Qu LL. Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: a case report. World J Clin Cases. 2022;10(23):8284\u201390. https:\/\/doi.org\/10.12998\/wjcc.v10.i23.8284.","journal-title":"World J Clin Cases"},{"issue":"1","key":"1755_CR100","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12890-021-01513-7","volume":"21","author":"SG Gray","year":"2021","unstructured":"Gray SG. Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma. BMC Pulm Med. 2021;21(1):148. https:\/\/doi.org\/10.1186\/s12890-021-01513-7.","journal-title":"BMC Pulm Med"},{"issue":"4","key":"1755_CR101","doi-asserted-by":"publisher","first-page":"192","DOI":"10.33696\/immunology.2.042","volume":"2","author":"A Klampatsa","year":"2020","unstructured":"Klampatsa A, Albelda SM. Current advances in CAR T cell therapy for malignant mesothelioma. J Cell Immunol. 2020;2(4):192\u2013200. https:\/\/doi.org\/10.33696\/immunology.2.042.","journal-title":"J Cell Immunol"},{"key":"1755_CR102","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.lungcan.2021.05.004","volume":"157","author":"NK Chintala","year":"2021","unstructured":"Chintala NK, Restle D, Quach H, Saini J, Bellis R, Offin M, et al. CAR T-cell therapy for pleural mesothelioma: rationale, preclinical development, and clinical trials. Lung Cancer. 2021;157:48\u201359. https:\/\/doi.org\/10.1016\/j.lungcan.2021.05.004.","journal-title":"Lung Cancer"},{"issue":"1","key":"1755_CR103","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40364-021-00264-1","volume":"9","author":"L Castelletti","year":"2021","unstructured":"Castelletti L, Yeo D, van Zandwijk N, Rasko JEJ. Anti-mesothelin CAR T cell therapy for malignant mesothelioma. Biomark Res. 2021;9(1):11. https:\/\/doi.org\/10.1186\/s40364-021-00264-1.","journal-title":"Biomark Res"},{"issue":"261","key":"1755_CR104","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","volume":"6","author":"PS Adusumilli","year":"2014","unstructured":"Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014;6(261):261ra151. https:\/\/doi.org\/10.1126\/scitranslmed.3010162.","journal-title":"Sci Transl Med"},{"issue":"8","key":"1755_CR105","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/jci83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130\u201344. https:\/\/doi.org\/10.1172\/jci83092.","journal-title":"J Clin Invest"},{"issue":"11","key":"1755_CR106","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.Cd-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli PS, Zauderer MG, Rivi\u00e8re I, Solomon SB, Rusch VW, O\u2019Cearbhaill RE, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 2021;11(11):2748\u201363. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-0407.","journal-title":"Cancer Discov"},{"issue":"10","key":"1755_CR107","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jtho.2016.06.021","volume":"11","author":"LA Lievense","year":"2016","unstructured":"Lievense LA, Cornelissen R, Bezemer K, Kaijen-Lambers ME, Hegmans JP, Aerts JG. Pleural effusion of patients with malignant mesothelioma induces macrophage-mediated T cell suppression. J Thorac Oncol. 2016;11(10):1755\u201364. https:\/\/doi.org\/10.1016\/j.jtho.2016.06.021.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1755_CR108","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.canlet.2012.02.034","volume":"322","author":"V Izzi","year":"2012","unstructured":"Izzi V, Masuelli L, Tresoldi I, Foti C, Modesti A, Bei R. Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies. Cancer Lett. 2012;322(1):18\u201334. https:\/\/doi.org\/10.1016\/j.canlet.2012.02.034.","journal-title":"Cancer Lett"},{"key":"1755_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2022.01.003","volume":"165","author":"M Ghosn","year":"2022","unstructured":"Ghosn M, Cheema W, Zhu A, Livschitz J, Maybody M, Boas FE, et al. Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I\/II clinical trial. Lung Cancer. 2022;165:1\u20139. https:\/\/doi.org\/10.1016\/j.lungcan.2022.01.003.","journal-title":"Lung Cancer"},{"issue":"4","key":"1755_CR110","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/mt.2009.309","volume":"18","author":"DH Sterman","year":"2010","unstructured":"Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT, et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther. 2010;18(4):852\u201360. https:\/\/doi.org\/10.1038\/mt.2009.309.","journal-title":"Mol Ther"},{"key":"1755_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2025.102720","volume":"62","author":"S Liu","year":"2025","unstructured":"Liu S, Li X, Wei W, Li N, Xu L, Huang W, et al. Translational selenium nanoparticles enhance NKG2D-mediated cytotoxicity of NK cells against malignant pleural mesothelioma cells through the TrxR1-pSTAT3 pathway. Nano Today. 2025;62:102720. https:\/\/doi.org\/10.1016\/j.nantod.2025.102720.","journal-title":"Nano Today"},{"issue":"5","key":"1755_CR112","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/cco.0000000000000388","volume":"29","author":"SG Warner","year":"2017","unstructured":"Warner SG, O\u2019Leary MP, Fong Y. Therapeutic oncolytic viruses: clinical advances and future directions. Curr Opin Oncol. 2017;29(5):359\u201365. https:\/\/doi.org\/10.1097\/cco.0000000000000388.","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"1755_CR113","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/ncponc0736","volume":"4","author":"TC Liu","year":"2007","unstructured":"Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol. 2007;4(2):101\u201317. https:\/\/doi.org\/10.1038\/ncponc0736.","journal-title":"Nat Clin Pract Oncol"},{"key":"1755_CR114","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00179","volume":"7","author":"DF Pease","year":"2017","unstructured":"Pease DF, Kratzke RA. Oncolytic viral therapy for mesothelioma. Front Oncol. 2017;7:179. https:\/\/doi.org\/10.3389\/fonc.2017.00179.","journal-title":"Front Oncol"},{"issue":"15 Pt 1","key":"1755_CR115","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1158\/1078-0432.Ccr-07-0403","volume":"13","author":"DH Sterman","year":"2007","unstructured":"Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A, et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res. 2007;13(15 Pt 1):4456\u201366. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-0403.","journal-title":"Clin Cancer Res"},{"key":"1755_CR116","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007552","author":"S Ponce","year":"2023","unstructured":"Ponce S, Cedr\u00e9s S, Ricordel C, Isambert N, Viteri S, Herrera-Juarez M, et al. ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-007552.","journal-title":"J Immunother Cancer"},{"key":"1755_CR117","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.lungcan.2020.10.007","volume":"150","author":"SJ Danson","year":"2020","unstructured":"Danson SJ, Conner J, Edwards JG, Blyth KG, Fisher PM, Muthana M, et al. Oncolytic herpesvirus therapy for mesothelioma: a phase I\/IIa trial of intrapleural administration of HSV1716. Lung Cancer. 2020;150:145\u201351. https:\/\/doi.org\/10.1016\/j.lungcan.2020.10.007.","journal-title":"Lung Cancer"},{"issue":"3","key":"1755_CR118","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/cas.15645","volume":"114","author":"K Okamura","year":"2023","unstructured":"Okamura K, Inoue H, Tanaka K, Ikematsu Y, Furukawa R, Ota K, et al. Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma. Cancer Sci. 2023;114(3):1095\u2013107. https:\/\/doi.org\/10.1111\/cas.15645.","journal-title":"Cancer Sci"},{"issue":"12","key":"1755_CR119","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03815-1","volume":"73","author":"K Sakura","year":"2024","unstructured":"Sakura K, Kuroyama M, Shintani Y, Funaki S, Atagi S, Kadota Y, et al. Dose-escalation, tolerability, and efficacy of intratumoral and subcutaneous injection of hemagglutinating virus of Japan envelope (HVJ-E) against chemotherapy-resistant malignant pleural mesothelioma: a clinical trial. Cancer Immunol Immunother. 2024;73(12):243. https:\/\/doi.org\/10.1007\/s00262-024-03815-1.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"1755_CR120","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1016\/j.jtho.2020.03.007","volume":"15","author":"H Yang","year":"2020","unstructured":"Yang H, Xu D, Gao Y, Schmid RA, Peng RW. Oncolytic viral therapy for malignant pleural mesothelioma. J Thorac Oncol. 2020;15(7):e111\u20133. https:\/\/doi.org\/10.1016\/j.jtho.2020.03.007.","journal-title":"J Thorac Oncol"},{"key":"1755_CR121","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.omto.2019.04.003","volume":"13","author":"V Sivanandam","year":"2019","unstructured":"Sivanandam V, LaRocca CJ, Chen NG, Fong Y, Warner SG. Oncolytic viruses and immune checkpoint inhibition: the best of both worlds. Mol Ther Oncolytics. 2019;13:93\u2013106. https:\/\/doi.org\/10.1016\/j.omto.2019.04.003.","journal-title":"Mol Ther Oncolytics"},{"issue":"5","key":"1755_CR122","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jtho.2019.12.128","volume":"15","author":"T Delaunay","year":"2020","unstructured":"Delaunay T, Achard C, Boisgerault N, Grard M, Petithomme T, Chatelain C, et al. Frequent homozygous deletions of type i interferon genes in pleural mesothelioma confer sensitivity to oncolytic measles virus. J Thorac Oncol. 2020;15(5):827\u201342. https:\/\/doi.org\/10.1016\/j.jtho.2019.12.128.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"1755_CR123","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00262-010-0871-8","volume":"59","author":"LM Krug","year":"2010","unstructured":"Krug LM, Dao T, Brown AB, Maslak P, Travis W, Bekele S, et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother. 2010;59(10):1467\u201379. https:\/\/doi.org\/10.1007\/s00262-010-0871-8.","journal-title":"Cancer Immunol Immunother"},{"issue":"24","key":"1755_CR124","doi-asserted-by":"publisher","first-page":"7483","DOI":"10.1158\/1078-0432.Ccr-17-2169","volume":"23","author":"MG Zauderer","year":"2017","unstructured":"Zauderer MG, Tsao AS, Dao T, Panageas K, Lai WV, Rimner A, et al. A randomized phase II trial of adjuvant Galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma. Clin Cancer Res. 2017;23(24):7483\u20139. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2169.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1755_CR125","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1164\/rccm.200312-1683OC","volume":"169","author":"F Ebstein","year":"2004","unstructured":"Ebstein F, Sapede C, Royer PJ, Marcq M, Ligeza-Poisson C, Barbieux I, et al. Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells. Am J Respir Crit Care Med. 2004;169(12):1322\u201330. https:\/\/doi.org\/10.1164\/rccm.200312-1683OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"1755_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050525","author":"DW Dumoulin","year":"2021","unstructured":"Dumoulin DW, Cornelissen R, Bezemer K, Baart SJ, Aerts J. Long-term follow-up of mesothelioma patients treated with dendritic cell therapy in three phase I\/II trials. Vaccines. 2021. https:\/\/doi.org\/10.3390\/vaccines9050525.","journal-title":"Vaccines"},{"issue":"9","key":"1755_CR127","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1164\/rccm.201512-2444ED","volume":"193","author":"T Peikert","year":"2016","unstructured":"Peikert T, Sterman DH. Harnessing the power of the host: improving dendritic cell vaccines for malignant pleural mesothelioma. Am J Respir Crit Care Med. 2016;193(9):943\u20135. https:\/\/doi.org\/10.1164\/rccm.201512-2444ED.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1755_CR128","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1158\/1078-0432.Ccr-17-2522","volume":"24","author":"J Aerts","year":"2018","unstructured":"Aerts J, de Goeje PL, Cornelissen R, Kaijen-Lambers MEH, Bezemer K, van der Leest CH, et al. Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human. Clin Cancer Res. 2018;24(4):766\u201376. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2522.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1755_CR129","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01661-x","volume":"18","author":"ZN Berneman","year":"2025","unstructured":"Berneman ZN, De Laere M, Germonpr\u00e9 P, Huizing MT, Willemen Y, Lion E, et al. WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome. J Hematol Oncol. 2025;18(1):9. https:\/\/doi.org\/10.1186\/s13045-025-01661-x.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"1755_CR130","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0307204","volume":"19","author":"J den Van Bossche","year":"2024","unstructured":"den Van Bossche J, De Laere M, Deschepper K, Germonpr\u00e9 P, Valcke Y, Lamont J, et al. Integration of the PD-L1 inhibitor atezolizumab and WT1\/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma: protocol of the Immuno-MESODEC study. PLoS One. 2024;19(7):e0307204. https:\/\/doi.org\/10.1371\/journal.pone.0307204.","journal-title":"PLoS One"},{"key":"1755_CR131","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd9882","author":"J Murakami","year":"2021","unstructured":"Murakami J, Wu L, Kohno M, Chan ML, Zhao Y, Yun Z, et al. Triple-modality therapy maximizes antitumor immune responses in a mouse model of mesothelioma. Sci Transl Med. 2021. https:\/\/doi.org\/10.1126\/scitranslmed.abd9882.","journal-title":"Sci Transl Med"},{"issue":"Suppl 1","key":"1755_CR132","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41379-021-00895-7","volume":"35","author":"S Dacic","year":"2022","unstructured":"Dacic S. Pleural mesothelioma classification-update and challenges. Mod Pathol. 2022;35(Suppl 1):51\u20136. https:\/\/doi.org\/10.1038\/s41379-021-00895-7.","journal-title":"Mod Pathol"},{"key":"1755_CR133","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.critrevonc.2016.08.011","volume":"107","author":"G Bronte","year":"2016","unstructured":"Bronte G, Incorvaia L, Rizzo S, Passiglia F, Galvano A, Rizzo F, et al. The resistance related to targeted therapy in malignant pleural mesothelioma: why has not the target been hit yet? Crit Rev Oncol Hematol. 2016;107:20\u201332. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.08.011.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"1755_CR134","doi-asserted-by":"publisher","first-page":"e565","DOI":"10.1016\/s2589-7500(21)00104-7","volume":"3","author":"MG Zauderer","year":"2021","unstructured":"Zauderer MG, Martin A, Egger J, Rizvi H, Offin M, Rimner A, et al. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study. Lancet Digit Health. 2021;3(9):e565\u201376. https:\/\/doi.org\/10.1016\/s2589-7500(21)00104-7.","journal-title":"Lancet Digit Health"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01755-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01755-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01755-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T11:23:27Z","timestamp":1771413807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01755-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":134,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1755"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01755-w","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"18 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"16"}}